4.5 Article

Presenting ADHD Symptoms, Subtypes, and Comorbid Disorders in Clinically Referred Adults With ADHD

期刊

JOURNAL OF CLINICAL PSYCHIATRY
卷 70, 期 11, 页码 1557-1562

出版社

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.08m04785pur

关键词

-

资金

  1. Abbott
  2. McNeil
  3. Eli Lilly
  4. National Institutes of Health [RO1 DA12945, K24 DA016264]
  5. Merck
  6. Shire
  7. Alza
  8. AstraZeneca
  9. Bristol-Myers Squibb
  10. Janssen
  11. Organon
  12. Otsuka
  13. National Institute of Mental Health (NIMH)
  14. National Institute of Child Health and Human Development
  15. Celltech
  16. Cephalon
  17. Esai
  18. Forest
  19. GlaxoSmithKline
  20. Gliatech
  21. NARSAD
  22. NIDA
  23. New River
  24. Novartis
  25. Noven
  26. Neurosearch
  27. Pfizer
  28. Pharmacia
  29. The Prechter Foundation
  30. The Stanley Foundation
  31. UCB Pharma

向作者/读者索取更多资源

Objective: Despite the increasing presentation of attention-deficit/hyperactivity disorder (ADHD) in adults, many practitioners remain reluctant to assess individuals for ADHD, in part related to the relative lack of data on the presenting symptoms of ADHD in adulthood. Comorbidity among adults with ADHD is also of great interest due to the high rates of psychiatric comorbidity, which can lead to a more persistent ADHD among adults. Method: We assessed 107 adults with ADHD of both sexes (51% female; mean +/- SD of 37 +/- 10.4 years) using structured diagnostic interviews. Using DSM-IV symptoms, we determined DSM-IV subtypes. The study was conducted from 1998 to 2003. Results: Inattentive symptoms were most frequently endorsed (> 90%) in adults with ADHD. Using current symptoms, 62% of adults had the combined subtype, 31% the inattentive only subtype, and 7% the hyperactive/impulsive only subtype. Adults with the combined subtype had relatively more psychiatric comorbidity compared to those with the predominately inattentive subtype. Women were similar to men in the presentation of ADHD. Conclusion: Adults with ADHD have prominent inattentive symptoms of ADHD, necessitating careful questioning of these symptoms when evaluating these individuals. J Clin Psychiatry 2009,70(11):1557-1562 (C) Copyright 2009 Physicians Postgraduate Press, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据